Marker Therapeutics, Inc. (MRKR)

Nasdaq Pharmaceutical Pharmaceutical Preparations SIC: 2834
D
Pipeline Grade

Financial Position (from SEC Filings)

$15.6M
Cash & Equivalents
$1.4M
Quarterly Burn Rate
33 mo
Est. Cash Runway
$25M
Market Cap

Estimated from most recent SEC quarterly filing. View SEC filings

Drug Pipeline (0 Assets)

No drugs indexed yet. Pipeline data is populated from ClinicalTrials.gov and openFDA.

Upcoming Catalysts

No upcoming catalysts detected for this company.

Active Clinical Trials (2)

NCT #TitlePhaseStatusEnrollment
NCT05798897 Safety and Preliminary Efficacy of MT-601 in Patients With Relapsed/Refractory Lymphoma PHASE1 Recruiting 79
NCT06552416 Safety of MT-401-OTS in Patients With Relapsed AML or MDS PHASE1 Recruiting 40

Source: ClinicalTrials.gov. Trial status last updated by sponsor — may not reflect current state.

More Analysis

AI Stock Score

SEC EDGAR fundamental analysis with Claude AI & ChatGPT ratings for MRKR.

SEC EDGAR Filings

All SEC filings for Marker Therapeutics, Inc. on EDGAR.

Full Calendar

View all upcoming FDA catalysts across all biotech companies.